We have discovered and developed a series of molecules (thiazole benzenesulfonamides). HA15, the lead compound of this series, displayed anti-cancerous activity on all melanoma cells tested, including cells isolated from patients and cells that developed resistance to BRAF inhibitors. Our molecule displayed activity against other liquid and solid tumors. HA15 also exhibited strong efficacy in xenograft mouse models with melanoma cells either sensitive or resistant to BRAF inhibitors. Transcriptomic, proteomic, and biochemical studies identified the chaperone BiP/GRP78/HSPA5 as the specific target of HA15 and demonstrated that the interaction increases ER stress, leading to melanoma cell death by concomitant induction of autophagic and apoptotic mechanisms.
INTRODUCTION
Cutaneous melanoma is a malignant tumor that develops from skin melanocytes, the cells responsible for the synthesis of melanins. The development of melanoma occurs in three major stages: the radial growth phase in which cells proliferate in the epidermis, the vertical growth phase involving an invasion of the dermis, and finally the metastatic phase corresponding to a Significance Melanoma is one of the most lethal cancers when it reaches the metastatic stage. Despite the spectacular progress made recently in the treatment of melanoma by using targeted therapies or immunotherapies, most patients with melanoma will need additional treatments. Using structure/activity relationship studies, we have discovered and developed a series of molecules (thiazole benzenesulfonamides) exhibiting strong lethal effects in melanoma cells. The lead compound HA15 displays anti-melanoma effects by targeting the ER stress axis, thereby highlighting the key role of this specific pathway in melanoma malignancy in particular and in cancer in general, and strengthening the idea that ER stress inducers could be useful in cancer treatment.
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Cutaneous melanoma has a high invasive capability and can rapidly metastasize to other organs. Metastatic melanoma is one of the most lethal cancers. With an incidence that doubles every 10 years, melanoma thus constitutes a serious public health issue. The prognosis of metastatic melanoma is extremely pejorative. Indeed, at the stage of visceral metastasis, the prognosis is catastrophic with a median survival of 6 months. Therefore, although melanoma represents only 5% of all cutaneous cancers, it is responsible for 80% of the deaths associated with skin cancers (Demierre, 2006) . Encouraging results have recently been obtained with BRAF inhibitors, vemurafenib or dabrafenib, and with MEK inhibitors (Smalley, 2010) . The life expectancy of patients is increased by about 6 months with use of these inhibitors (Aplin et al., 2011; Flaherty et al., 2010 Flaherty et al., , 2012 . Regrettably, however, after a short period of remission, melanomas acquire drug resistance, and recurrence of metastases is observed in almost all cases. Numerous studies have focused on identifying the resistance mechanisms. These studies have disclosed the existence of highly heterogeneous processes but most lead to restoration of MAPK signaling or maintenance of translation (Boussemart et al., 2014; Goding, 2013; Wong and Ribas, 2016) . Other therapies, anti-CTLA4 and anti-PD1, recently developed to reactivate the anti-tumor immune response of the patient (Eggermont et al., 2014; Zeiser et al., 2012) result in an objective and long-lasting response in about 15%-35% of patients. Nevertheless, despite the recent improvements in melanoma treatment, more than 50% of patients will be in treatment failure. Therefore, identification of a common vulnerability in melanoma cells is an urgent need and will help to discover more effective treatments of melanoma.
We have previously demonstrated the capacity for molecules of the thiazolidinedione (TZD) family to induce massive death of melanoma cell lines (Botton et al., 2009 . TZDs are known previously for their use in the treatment of type 2 diabetes, in which they activate peroxisome proliferator-activated receptor g (PPARg), a nuclear receptor of target cells, to increase insulin sensitivity (Auwerx, 1999) . Interestingly, their action on melanoma is independent of PPARg activation (Botton et al., 2009) . Based on these results, we initiated a chemistry program aimed at modifying the structure of the TZDs to eliminate any PPARg activation properties while maintaining the strong anti-melanoma activity.
RESULTS

HA15 Exerts a Deleterious Effect on Melanoma Cell
Viability By iterative structure-activity studies requiring the synthesis and testing of a large number of analog molecules, the structure of TZD was deeply modified and ultimately led to establishing the lead compound HA15. Figure 1A presents the structures of troglitazone and our lead compound HA15, belonging to the thiazole benzensulfonamides. As expected from its structure, which lacks the TZD moiety, HA15 does not bind or activate PPARg (data not shown).
The effect of HA15 on human melanoma cell lines was evaluated using the trypan blue exclusion assay. Time course experiments showed that after 6 hr of incubation, HA15 (10 mM) decreased melanoma cell viability compared with control conditions (DMSO) ( Figure 1B ). After 48 hr of HA15 treatment, only 3% of melanoma cells were still viable. As shown in Figure 1C , 24 hr exposure to various concentrations of HA15 led to a dose-dependent decrease in melanoma cell viability. The 50% inhibitory concentration (IC 50 ) in A375 cells was between 1 and 2.5 mM HA15. HA15 decreased the viability of melanoma cell lines with different mutational status ( Figures 1D and S1 ). These results were further confirmed using melanoma cell cultures freshly isolated from patient tumors with BRAF mutation (patients 1 and 4), with BRAF and TP53 mutations (patient 2), and with NRAS mutation (patients 3 and 5, Figure 1E ). Importantly, no deleterious effects on the viability of normal human melanocytes or human fibroblasts were observed with low or high doses of HA15 (10 and 100 mM, respectively; Figure 1F ).
HA15 Induces an Early ER Stress
To investigate the signaling pathway involved in the effects of HA15 on melanoma cells, we performed microarray analysis in which three different melanoma cell lines, Mel501, SKMel28, and A375, were treated for 6 hr with 10 mM HA15. Gene set enrichment analysis (GSEA) revealed a significant increase in all three cells lines of genes involved in the unfolded protein response leading to ER stress, such as EIF2AK3 (PERK), ATF4, ERN1 (IRE1a), ATF6, DDIT3 (CHOP), and XBP1 ( Figure 2A ). Several other genes whose expression was also found to be increased are involved in apoptosis (JUN, BCL2) or autophagy (LC3) (data not shown). To characterize the ER stress, we studied the key players of ER stress by western blot analysis on the lysate of A375 cells treated for different times with 10 mM HA15 ( Figure 2B ). After only 1 hr of HA15 treatment, we observed phosphorylation of PERK and elF2a and a weak increase in ATF4 and CHOP expression. After 4 hr of HA15 treatment, the expression of IRE1a, ATF4, and CHOP had strongly increased, and PERK and elF2a remained phosphorylated. This increase in expression and phosphorylation persisted after 24 hr of treatment. The protein kinase activated by double-stranded RNA (PKR) activation is generally associated with auto-phosphorylation and electrophoretic shift. HA15 does not change PKR migration in a western blot, indicating that HA15 does not activate PKR in melanoma cells. Therefore, PKR cannot be responsible for eIF2a phosphorylation. In parallel, splicing of XBP1 mRNA was induced after 1 hr of HA15 treatment, which persisted after 24 hr ( Figure 2C ). These results indicate a rapid induction, within 1 hr, of the ER stress markers by HA15. Furthermore, electron microscopy revealed that the melanoma cells exposed to HA15 (10 mM) over 12 hr presented a typical dilated ER cisternae, a classical feature of ER stress ( Figure 2D ).
To confirm the involvement of HA15 in the induction of ER stress, we analyzed the localization of HA15 using auto-fluorescence of its dansyl ring and subsequent confocal analysis (Figure 2E ). We observed a strong co-localization between HA15 and ER Tracker. Quantification of 100 individual cells showed that 82% ± 11% of the HA15 labeling overlapped with that of the ER Tracker, thus highlighting an interaction of HA15 with the ER. Finally, we observed that HA15 also induced ER stress in other melanoma cell lines by the increased expression of PERK, IRE1a, ATF4, CHOP, and phosphorylation of elF2a ( Figure 2F ).
Determination of the Molecular Target of HA15
To determine the molecular target of HA15 within the ER, a chemical probe was designed allowing streptavidin affinity purification of the HA15 interactors for proteomic analysis. A biotin moiety was attached on the amide part of HA15 or of the inactive compound AM406 ( Figure 3A ), spaced by a 10 atom linker to avoid any hindering to the binding between HA15 and its target. Cell viability assays confirmed similar levels of activity between HA15-biotin and HA15. AM406-biotin has no effect on cell viability ( Figure S2A ).
Lysates of A375 melanoma cells were incubated with HA15-biotin before being precipitated using streptavidin beads, as described in the Experimental Procedures. Precipitated biotinstreptavidin complexes were separated on SDS-PAGE, and the proteins were then identified using proteomic analysis. For (B-F) , the results are expressed as percentages of the control and data are means ± SD of three independent experiments performed in triplicate. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S1 .
represents the different proteins found to interact specifically with HA15-biotin. Considering the observed dependence on ER stress of HA15-induced effects, we focused our attention on proteins that play a role in this process. Interestingly, we identify the chaperone protein glucose-regulated protein 78 (GRP78, also named HSPA5 or binding immunoglobulin protein BiP), known to play a pivotal role in ER stress response, as a direct target of HA15. To confirm the interaction between HA15 and BiP, we performed pull-down assays using HA15-biotin or the inactive AM406-biotin and recombinant proteins (IRE1a, ATF6, BiP, and HSP70). HA15 and AM406 biotin derivatives do not interact with recombinant IRE1a, ATF6, or HSP70 recombinant proteins ( Figure 3B ). However, we observed an interaction between BiP and HA15-biotin, but not with AM406-biotin (Figure 3B ). In parallel, lysates from A375 melanoma cells were incubated with HA15-biotin, biotin alone, or AM406-biotin before being precipitated using streptavidin beads and separated on SDS-PAGE. The precipitated proteins were identified by western blot using specific antibody ( Figure 3C ). We found that HA15-biotin interacts with BiP, but not with PERK, ATF6, IRE1a, or HSP70. As expected, biotin or AM406-biotin interacts with none of these proteins, demonstrating therefore a specific interaction between BiP and HA15. Similar results were found with cell lysates from melanoma cells isolated from patients (Figure S2B ), indicating that HA15 and BiP interaction is not restricted to A375 cells. Then, we hypothesized that the interaction between BiP and HA15 is responsible for the dissociation of BiP with its ER partners, PERK, IRE1a, and ATF6, therefore representing the initial event necessary to induce the observed ER stress. Co-immunoprecipitation experiments showed that incubation of melanoma cell lysates with HA15 decreased the BiP level in the PERK, IRE1a, and ATF6 immunoprecipitated fractions ( Figures 3D  and S2C ), thus confirming our hypothesis that HA15 induced a dissociation of the BiP, PERK, IRE1a, and ATF6 complex. In other series of experiments of co-immunoprecipitation, we found that addition of recombinant BiP competes and diminishes dissociation of endogenous cellular BiP from PERK and IRE1a ( Figure S2D) . We next performed an in vitro reconstitution assay using recombinant BiP and recombinant IRE1a. As presented in Figure S2E , contrary to the inactive derivative AM406, HA15 is able to dissociate the complex between BiP and IRE1a, suggesting a direct effect of HA15 on the complex. We next used immunofluorescent microscopy to investigate whether HA15 and BiP co-localized in the cell. As shown in Figure 3E , HA15 showed a strong co-localization with BiP antibody and ER Tracker. Quantification of 100 individual cells indicated that 64% ± 8% of HA15 labeling co-localized with that of BiP, further supporting an interaction between HA15 with BiP. Figure S2F indicates that there is no crosstalk between the three channels. Finally, fluorescence resonance energy transfer analysis and experiments using differential scanning calorimetry or isothermal titration microcalorimetry (ITC) confirmed the interaction between BiP and HA15 ( Figures S3A-S3C ).
All HSP70-family proteins require ATP binding and hydrolysis to ensure their chaperone function. BiP would therefore be expected to depend on its functional ATP-binding domain to induce its unfolded protein response (UPR)-adaptive effect. The HSP70s bind ATP with high affinity and their ATPase activity, stimulated by binding to the unfolded protein, catalyzes refolding. In contrast to the biphenolic compound honokiol derived from Magnolia officianalis (Martin et al., 2013) , which was described to interact with BiP, HA15 is able to inhibit the ATPase activity of BiP in a dose-dependent manner ( Figure 3F ). Taken together, these results demonstrate that HA15 directly binds to and inhibits BiP activity. We finally demonstrated that BiP expression increased during melanoma development (Figures S3D and S3E; Table S1 ) and that melanoma cells expressing a high level of BiP (e.g., A375 and patient 2) responded to HA15 better than those expressing a low level of BiP (e.g., Skmel28 and patient 5) ( Figure S3F ).
HA15 Induces Concomitant Autophagy and Apoptosis
Electron microscopic images of A375 cells treated for 24 hr with HA15 displayed membrane blebs characteristic of apoptotic cells ( Figure 4A ). By contrast, the control melanoma cells (DMSO) showed no autophagic vacuoles or membrane blebbing. HA15-treated cells also displayed an increase in annexin V labeling ( Figure 4B ) and a decrease in expression of the antiapoptotic protein BCL2 ( Figure 4C , upper part). HA15 at 10 mM strongly increased the levels of the cleaved and activated form of caspase 9 that initiates apoptosis through the mitochondrial intrinsic pathway. Concordantly, the zymogenic form of caspase 3 showed reduced levels, indicative of its activation. One of the best described cellular substrates of activated caspase 3 is poly(ADP-ribose) polymerase (PARP), and stimulation of cells with 10 mM HA15 led to cleavage of PARP. As expected, the treatment of cells with the pancaspase inhibitor Q-VD-OPH (QVD, 20 mM) abolished the effect of HA15 on PARP cleavage ( Figure 4C , lower part). Collectively, these data indicate that HA15 induces apoptosis.
Furthermore, electron microscopy images also showed typical signs of autophagy, including accumulation of numerous vesicles with a distinct double membrane ( Figure 4A ). They also displayed evidence of early autophagosomes sequestering cytosol, mitochondria, or ER membranes. These ultra-structural hallmarks of autophagy led us to investigate whether HA15 might also induce autophagy. During autophagy, LC3B-I is converted to LC3B-II through the ATG4-dependent insertion of a phosphoethanolamine moiety before being recruited into the membrane of the forming phagophore, a double membrane required for the recycling of protein aggregates and organelles (Klionsky et al., 2012) . Increased LC3B-II expression was detected after 1 hr of HA15 treatment and persisted after 24 hr ( Figure 4D ). At the same time, HA15 also enhanced the expression level of Beclin 1, a protein required to initiate the formation of the autophagosome in autophagy. Finally, we studied LC3B expression by immunofluorescence. Melanoma cells treated with HA15 showed a dramatic and sustained increase in LC3B staining compared with control ( Figure 4E ). These data were confirmed by fluorescence quantification and clearly indicate that HA15 also induces autophagy.
Considering that a strong and sustained ER stress can lead to cell death by apoptosis and sometimes autophagy, we wished to determine whether the ER stress induced by HA15 is responsible for apoptosis, autophagy, and finally melanoma cell death. To this end, we blocked ER stress by inhibiting the expression of CHOP, a key player in ER stress, using siRNA. As expected, siRNA against CHOP completely inhibited the expression of CHOP protein both basally and in response to HA15 ( Figure 4F ). The expressions of two proteins upstream of CHOP, PERK, and IRE1a, were not modified by the siRNA. Interestingly, reduction of CHOP dramatically inhibited PARP cleavage and the conversion of LC3B-I to LC3B-II. Concomitantly, siCHOP prevented the decrease in cell viability induced by HA15, demonstrating that ER stress is responsible for melanoma cell death ( Figure 4F ). (B) Lysates from A375 melanoma cells exposed for the indicated durations to HA15 were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. (C) XBP1 mRNA splicing was detected with RT-PCR. GAPDH was used to confirm the quality and quantity of RNA. 
(legend continued on next page)
Silencing of other ER stress signaling pathway proteins, PERK, IRE1a, and ATF4 ( Figures S4A and S4B ), partially reverses the effect of HA15 on cell viability. As a whole, these results indicate that apoptosis, autophagy, and finally melanoma cell death are the consequences of HA15-induced ER stress. Finally, we studied the respective contribution of apoptosis and autophagy in the cell death induced by HA15. We thus blocked apoptosis and autophagy using QVD and siLC3, respectively. QVD and siLC3B inhibited PARP cleavage and LC3B expression respectively in the presence or absence of HA15 treatment. As expected, neither QVD nor siLC3B modified ER stress induced by HA15, as monitored by the increase in expression of IRE1a and CHOP. Inhibition of apoptosis or autophagy partially inhibited the cell death induced by HA15, whereas concomitant inhibition of both completely restored cell viability ( Figure 4G ). Taken together, these data indicate that apoptosis and autophagy act simultaneously in HA15-induced melanoma cell death.
Interestingly, HA15 did not induce PARP cleavage in normal melanocytes and normal fibroblasts, suggestive of an absence of apoptosis ( Figure 4H ). This is consistent with the absence of death found in these cells upon HA15 treatment. CHOP was not detectable in normal cells and HA15 slightly increased CHOP protein levels in melanocytes but not in fibroblasts. As expected, HA15 strongly increased the CHOP level in A375 melanoma cells. BiP protein is expressed in fibroblasts but its expression is not induced by HA15. The slight increase of BiP in melanocytes is, however, not comparable with the strong increase observed in A375 melanoma cells. These results suggest that HA15 does not modulate ER stress in normal melanocytes and fibroblasts, explaining its lack of toxicity in normal cells.
ER stress has also been shown to promote mitochondrial membrane depolarization and reactive oxygen species (ROS) production. The ROS inhibitor N-acetyl-L-cysteine attenuated the cell death-inducing effect of HA15 ( Figure S4C ), suggesting that ROS induced by ER stress could be involved in the effects of HA15.
HA15 Inhibits Melanoma Tumor Development in Mice
To assess a potential antineoplastic effect of HA15 in vivo, A375 melanoma cells (1.5 3 10 6 ) were injected subcutaneously into 6-week-old female athymic nude mice that were treated 8 days later by injection of vehicle, PLX4032 (0.7 mg/mouse/ day) or HA15 (0.7 mg/mouse/day) over a period of 2 weeks. Untreated control mice rapidly developed visible tumors, and we observed dramatic tumor growth throughout the study (Figure 5A ). In contrast, treatment of mice with PLX4032 or HA15 markedly attenuated the development of tumors. Moreover, the tumors derived from HA15-treated mice were consistently and significantly lighter than those from untreated control mice ( Figure 5B ). These data clearly demonstrate an anti-melanoma activity of HA15 in vivo, comparable with PLX4032 at the same dose. Furthermore, the treatment of mice with HA15 induced no apparent toxicity and we noted no change in their behavior, body mass, or liver mass, suggesting an absence of hepatomegaly ( Figures 5C and 5D ). We then investigated the molecular mechanisms involved in the anti-tumorigenic effects of HA15 in vivo. Tumor sections from mice treated with HA15, and to a much lesser extent with PLX4032, showed an increase in CHOP staining compared with control sections. In addition, the evaluation of apoptosis by TUNEL assay showed increased apoptosis in tumor sections from mice treated with HA15 compared with those from mice treated with vehicle or PLX4032 ( Figure 5E ). Similar results were found concerning autophagy showing an increase of LC3B staining as well as LC3B puncta, reminiscent of autophagosome formation in tumor sections from mice treated with HA15 ( Figure 5F ). Thus, the reduction in tumor volume and weight observed in the HA15-treated mice is, at least in part, the consequence of the induction of ER stress, autophagy, and apoptosis.
Finally, we evaluated the toxicity in the liver of mice treated with vehicle, HA15, or PLX4032. H&E staining of the liver of mice treated by HA15 and PLX showed normal histology when (D) PERK, IRE1a, and ATF6 were immunoprecipitated overnight from A375 lysates in the presence of DMSO or HA15. Western blotting was performed with indicated antibodies. One representative experiment of three is shown. (E) Immunofluorescence pictures of A375 melanoma cells treated with DSMO or 10 mM HA15 for 6 hr. ER was labeled with ER Tracker, BiP was labeled with antibody, and HA15 was visualized after an excitation at 405 nm. (F) BiP activity measurement on A375 melanoma cells treated with HA15, honokiol (HNK), or DMSO. The results are expressed as percentages of control (DMSO). Data are means ± SD of three independent experiments performed in triplicate. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figures S2 and S3; Table S1 . compared with control mice ( Figure 5G ). Hepatic transaminases measured from sera of treated mice ( Figure 5H) were not affected by HA15 or PLX4032 treatments, indicating an absence of hepatic toxicity induced by HA15 treatment.
HA15 Is Able to Induce Death of Melanoma Cells that Are Resistant to BRAF Inhibitors As mentioned above, treatment of BRAF V600E melanoma patients with BRAF inhibitors leads to systemic resistance and metastasis relapse. We wished to determine the efficacy of HA15 on melanoma cells resistant to BRAF inhibitors such as PLX4032. As presented in Figure 6A , HA15 was able to decrease the viability of A375 melanoma cells that had acquired resistance to PLX4032, as previously described (Corazao-Rozas et al., 2013) . The HA15 was also able to induce ER stress in these resistant cells, as shown by the increase in CHOP expression. We obtained the same results with SKMel28 and WM9, melanoma cells resistant to BRAF inhibitor ( Figure 6A ). In a more physiopathological approach, we tested our compound on melanoma cells isolated from biopsy samples of patients whose tumors had acquired resistance to BRAF inhibitors, PLX4032, or dabrafenib. Contrary to PLX4032 or dabrafenib, HA15 demonstrated high efficiency in inducing cell death and ER stress in BRAF-inhibitor-resistant melanoma cells ( Figure 6B ).
Finally, we tested the anti-tumorigenic effect of HA15 in mice injected with melanoma cells presenting acquired resistance to the BRAF inhibitor PLX4032. Briefly, as previously described, we subcutaneously injected BRAF-inhibitor-resistant A375 cells (1.5 3 10 6 ) into nude mice, which were then treated, 4 days later, by vehicle, PLX4032 (0.7 mg/mouse/day) or HA15 (0.7 mg/mouse/day). Untreated control mice or PLX-treated mice rapidly developed dramatic tumor growth throughout the study ( Figure 6C ). In contrast, treatment of mice with HA15 markedly attenuated the development of tumors. Moreover, tumors derived from HA15-treated mice were consistently and significantly lighter than those from the untreated control or PLX-treated mice ( Figure 6D) . These data clearly demonstrate anti-melanoma activity of HA15 in vivo in BRAF-inhibitor-resistant cells. As observed in tumors from BRAF-inhibitor-sensitive melanoma cells, HA15 induced a dramatic increase in CHOP staining compared with sections from control mice or mice injected with PLX4032 ( Figure 6E ). We also observed an increase in TUNEL-positive cells ( Figure 6E ) and an increase of LC3B staining as well as LC3B puncta ( Figure 6F ) in tumor sections from mice treated with HA15 compared with those from mice treated with vehicle or PLX4032.
HA15 Is Able to Induce Death of Cell Lines Derived from Numerous Other Tumors
Considering that ER stress is increased during the development of several types of tumors, we wondered whether HA15 could induce the death of other tumor cells. As presented in Figures  7A and 7B, HA15 treatment led to the death of cell lines derived from various tumor types. More interestingly, HA15-induced cell death was observed in cancer cells that are resistant to conventional therapy such as the pancreatic cell line MIA PaCa (resistant to gemcitabine) or the myeloid leukemia cells, ImaR (resistant to imatinib). Finally, we treated six non-melanoma cell lines with HA15 and determined its effects on ER stress and cell death ( Figure 7C ). HA15 induced an increase in CHOP expression and subsequent ER stress in all cell lines tested. Moreover, HA15 induced apoptosis (as monitored by PARP cleavage) in all tested cell lines. However, induction of autophagy (as monitored by conversion of LC3) was observed only on MDA-MB453, HT29, and MiaPaCa cells.
DISCUSSION
The discovery of therapeutic compounds for treating advanced melanomas that are resistant to existing therapies is paramount to further improve patient outcome. In the present report, we describe a lead compound of the thiazole benzenesulfonamides (D) A375 melanoma cell lines were treated with 10 mM HA15 for the indicated periods of time and their lysates were analyzed by western blotting using the indicated antibodies. HSP90 were used as a loading control. One representative experiment of three is shown. (E) Immunofluorescence pictures of A375 melanoma cells treated with DMSO or 10 mM HA15 for 24 hr. LC3B was labeled with antibody (green) and DNA was visualized with DAPI (blue). Quantifications of LC3B fluorescence intensity are presented in a.u. and represent means ± SD of three independent fields. ***p < 0.001. (F) A375 melanoma cells were transfected with siRNA against CHOP (siCHOP) or siRNA control (siCtl). 24 hr after transfection, cells were treated with HA15 at the indicated concentrations or DMSO for 48 hr. Viability of the cells was estimated by trypan blue staining. The results are expressed as percentages of the control. Data are means ± SD of three independent experiments performed in triplicate. ***p < 0.001. In parallel, cells were lysed and analyzed by western blotting using the indicated antibodies. HSP90 was used as a loading control. One representative experiment of three is shown. (G) A375 melanoma cells were transfected with a siRNA against LC3 (siLC3) or siRNA control (siCtl) and treated with QVD or DMSO. 24 hr after transfection, cells were treated with 10 mM HA15 or DMSO for 48 hr. Viability of the cells was estimated by trypan blue staining. The results are expressed as percentages of the control. Data are means ± SD of three independent experiments performed in triplicate. **p < 0.01; ***p < 0.001; #p < 0.05. In parallel, cells were lysed and analyzed by western blotting using the indicated antibodies. HSP60 was used as a loading control. One representative experiment of three is shown. (H) Normal human fibroblasts (NHF), normal human melanocytes (NHM), and A375 melanoma cells were treated for 48 hr with HA15 (10 mM). Cell lysates were separated by SDS-PAGE and analyzed by western blotting using the indicated antibody. HSP60 was used as a loading control. One representative experiment of three is shown. See also Figure series, denoted as HA15, that displays strong in vitro and in vivo anti-melanoma properties without toxicity in normal cells, predicting weak adverse effects of this compound. The death of melanoma cells induced by HA15 is mediated by the concomitant induction of autophagy and apoptosis, both of which are the consequence of a rapid initiation of ER stress. ER stress activates the UPR signaling network to alleviate such stress and restore ER homeostasis, thereby promoting cell survival and adaptation (Ellgaard and Helenius, 2003; Sitia and Braakman, 2003) . However, under irresolvable ER stress conditions, the UPR promotes cell death by triggering apoptosis and/or autophagy (Heath-Engel et al., 2008; Logue et al., 2013; Nagelkerke et al., 2014) . Inhibition of CHOP, a transcription factor that is involved in the induction of autophagy and apoptosis under high levels of ER stress (Szegezdi et al., 2006 ) prevents apoptosis and autophagy induced by HA15, thus demonstrating the causal role of ER stress in the anti-melanoma effect of HA15. Similarly, inhibition of other ER stress signaling pathway proteins partially reverses the effect of HA15 on cell viability, suggesting the effects of HA15 are also PERK/IRE1a dependent.
Autophagy is a catabolic process for the degradation and recycling of macromolecules and organelles, and is activated during stress conditions (Meijer and Codogno, 2004; Scarlatti et al., 2009) . It is considered as a survival mechanism induced in adverse conditions to maintain cell integrity, however, autophagy is also involved in a particular mode of death called type II cell death (Morselli et al., 2009 ). Several reports have described that the induction of autophagy by ER stress in melanoma and different tumor cells is responsible for their survival (Heath-Engel et al., 2008; Hoyer-Hansen and Jaattela, 2007; Ma et al., 2014; Rouschop et al., 2013) . On the other hand, prolonged ER stress and sustained autophagy may eventually lead to cell death. Interestingly, we observed that the blocking of autophagy by siRNA directed against LC3B or pharmacological inhibition by 3-methyl adenine (data not shown) restored partial melanoma cell survival in response to HA15 (approximately 50%). Moreover, during ER stress, PERK activation increases the transcription of autophagy genes MAP1LC3B, encoding LC3B, and ATG5 through the transcription factor ATF4 and CHOP, respectively (Rouschop et al., 2010) . In our hands, ATF4 silencing partially restores cell viability in response to HA15 and decreases HA15-stimulated LC3B I and II levels, but does not affect HA15-induced apoptosis. Therefore, ATF4 is involved in HA15-induced autophagy but not in the induction of apoptosis elicited by the compound. Simultaneous inhibition of apoptosis and autophagy completely blocked HA15-induced cell death, suggesting an equal contribution of both cell death mechanisms.
Mass spectrometry analysis of the proteins interacting with HA15 identified the chaperone BiP that is involved in the initial step of ER stress. Residing primarily in the ER, BiP belongs to the heat shock protein 70 (HSP70) family, which collectively play critical roles in oncogenic stress. In addition to facilitating proper protein folding, preventing intermediates clumping and targeting misfolded proteins for proteasome degradation, BiP also binds Ca 2+ and serves as an ER stress signaling regulator (Lee, 2007) . In non-stressed cells, BiP binds to other ER transmembrane sensors PERK, IRE1a, and ATF6 and maintains them in inactive form. Dissociation of BiP from these protein complexes activates their corresponding signaling pathways, sending signals to the nucleus and triggering the UPR (Szegezdi et al., 2006) . The identification of BiP as the target of our compound is a key discovery since this protein was reported to be the key regulator of chemoresistance. Indeed, the overexpression of BiP is a common observation in many tumors and clearly correlates with chemoresistance of several cancers including melanoma (Ma et al., 2014; Roller and Maddalo, 2013; Shenolikar, 2014) . Moreover, several results obtained in chemoresistant cancers have revealed the upregulation of BiP at both the RNA and protein expression levels (Guan et al., 2015; Li and Li, 2012; Roller and Maddalo, 2013; Zhuang et al., 2009) .
The data in mice associated with the lack of effect in normal cells (melanocytes and fibroblasts) demonstrate a specificity of HA15 for melanoma cells and an apparent lack of toxicity. Complementary studies confirming the absence of toxicity of the compound are ongoing. A higher basal level of ER stress in melanoma cells compared with normal cells may explain this interesting observation. By increasing the level of ER stress, HA15 may allow the threshold required to induce cell death in cancer cells but not in normal cells to be reached. This hypothesis is consistent with the results indicating that BiP expression is increased in melanoma cells in comparison with normal melanocytes.
Considering the role that BiP plays in chemoresistance both inside and outside the ER, developing therapeutic agents that directly target and inhibit the pro-survival action of this protein appears to be an important strategy. Further, we found that melanoma cells that express high levels of BiP in general are more sensitive to HA15 than are cells that express low levels of BiP, but there are clear exceptions. These exceptions may be explained by the fact that the degree of ER stress is not only determined by the level of BiP but also by the levels of its client proteins and downstream effectors that are also critical for the ER stress response. One major problem of all known inducers of ER stress mediated by BiP targeting is the presence of major off-target responses. For example, while honokiol is able to induce apoptosis in cancer cells (Chen et al., 2010; Martin et al., 2013) , it also induces the death of normal fibroblasts, melanocytes, and keratinocytes (data not shown) and is involved in the regulation of other pathways such as AMPK or Notch1 (Kaushik et al., 2014a (Kaushik et al., , 2014b . Further, our experiments indicate that unlike HA15, honokiol is unable to inhibit BiP activity. Another good example is epigallocatechin gallate (EGCG). This compound induces a weak ER stress response by interaction with BiP (Martin et al., 2013) but is also able to induce other responses such as inhibition of telomerase and DNA methyltransferase to block the activation of EGFR and HER2 and inhibition of fatty acid synthase and glutamate dehydrogenase (Khan and Mukhtar, 2008; Patra et al., 2008; Singh et al., 2011) .
The development of resistance to BRAF inhibitors is a major obstacle in targeted therapy for melanoma. HA15 reduces the development of melanoma tumors, including those from melanoma cells with acquired resistance to BRAF inhibitor. Therefore, HA15 is a reasonable candidate for therapeutic evaluation in (E) Frozen sections of tumors from mice treated with vehicle, HA15, or PLX were fixed and stained using CHOP antibody (red), DAPI (blue), or using TUNEL assay (green). Slides were examined with a Zeiss fluorescence microscope. Representative sections are shown. The experiment was repeated on sections from three mice per condition. Quantifications of TUNEL and CHOP fluorescence intensity are presented in a.u. and represent means ± SD of three independent fields. *p < 0.05. (F) Frozen sections of tumors from mice treated with vehicle, HA15, or PLX were fixed and stained using LC3B antibody (green) or DAPI (blue). Slides were examined with a Zeiss fluorescence microscope. Representative sections are shown. The experiment was repeated on sections from three mice per condition. Quantifications of LC3B fluorescence intensity are presented in a.u. and represent means ± SD of three independent fields. *p < 0.05. patients whose tumors have acquired resistance to BRAF inhibitors. Interestingly, we were unable to generate melanoma models of HA15 acquired resistance (data not shown) as obtained with BRAF inhibitors (Corazao-Rozas et al., 2013) . This result is not really surprising since HA15 affects a global cellular mechanism, i.e., ER stress, rather than one specific protein, as the BRAF inhibitors do. As an increase in ER stress is a common phenomenon found in most human tumors, we found that HA15 was also able to induce ER stress and showed a significant efficiency in all tumor cell lines tested regardless of tumor types, including those from tumors resistant to classical chemotherapy.
In summary, we demonstrate that HA15 inhibits tumor growth through autophagic and apoptotic mechanisms initiated by ER stress. Taking account of the drastic effect of HA15 on cancer growth in mice, together with the lack of apparent toxicity, this study provides compelling data to support the future evaluation of HA15 in clinical trials and strengthens the idea that ER stress inducers could be useful, alone, or in combination, as a new therapeutic approach in cancer treatment.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
Trypan blue, DMEM, RPMI, penicillin/streptomycin, trypsin, Hoechst, TUNEL assay, siRNA against CHOP, and XBP1 primers were purchased from Life Technologies and fetal calf serum (FCS) from was purchased from Hyclone. MCDB 153 medium and biotin were purchased from Sigma-Aldrich. Labrafils M1944 Cs was purchased from Gattefossé . Annexin V and DAPI were purchased from Roche Applied Science. ER Tracker was purchased from Molecular Probes. Dabrafenib and PLX4032 were purchased from Euromedex.
Cell Cultures
Normal human melanocytes and fibroblasts were prepared and maintained as described . Different melanoma cell lines were purchased from the American Tissue Culture Collection. Resistant melanoma cell lines A375 and SKMel28 were a gift from Professor P. Marchetti and described in Corazao-Rozas et al. (2013) . Cells were grown in RPMI 1640 or in DMEM supplemented with 10% FCS and penicillin/streptomycin (100 U/ml/50 mg/ml) at 37 C and 5% CO 2 . Fresh sterile tissues were obtained from surgical waste from patients diagnosed with metastatic melanoma at the Nice CHU hospital and treated as reported (Cerezo et al., 2013) . See Supplemental Experimental Procedures for cell preparation. Written informed consent was obtained from each patient included in this study, and the study was approved by the hospital ethics committee (Nice Hospital Center and University of Nice Sophia Antipolis, no. 210-2998). For each experiment, cells were starved without serum for 14 hr before drug stimulation.
SiRNA Transfection
Transfection of duplex siRNAs (50 nmol/l) was carried out using Lipofectamine RNAiMAX (Invitrogen) in OptiMEM (Invitrogen) as described (Botton et al., 2009) .
Trypan Blue Exclusion Assay
For trypan blue staining, 200 ml of cells was aseptically transferred to a 1.5 ml clear Eppendorf tube and incubated for 3 min at room temperature with an equal volume of 0.4% trypan blue solution. Viable cells were counted and the results are expressed as the percentage of the value of control cells. All the experiments are performed 3 times in triplicate.
Western Blot Assays
Western blot analyses were performed as described (Lehraiki et al., 2014) . Proteins were extracted in buffer containing 50 mmol/l Tris-HCl (pH 7.5), 15 mmol/l NaCl, 1% Triton X-100, and 1X protease and phosphatase inhibitors. Briefly, cell lysates (30 mg) were separated by SDS-PAGE, transferred onto a polyvinylidene fluoride membrane (Millipore), and then exposed to the appropriate antibodies. Proteins were visualized with the ECL System from Amersham. The western blot analyses shown are representative of at least three independent experiments. (C) Indicated cells were exposed during 48 hr to 10 mM HA15. Lysates were analyzed by western blotting using the indicated antibodies. One representative experiment of three is show.
Immunofluorescence
Immunofluorescence staining was performed as described (Cerezo et al., 2013) . For co-localization experiments, cells were incubated with ER Tracker for 15 min at 37 C. After washing, HA15 and ER staining was observed directly on live cells with the 403 objective using a Zeiss microscope. Cells were then fixed and permeabilized as describe above and then exposed to a BiP antibody overnight at 4 C. Cells were then incubated with fluorescein isothiocyanate-coupled anti-rabbit antibody for 1 hr at room temperature.
Flow Cytometry Analysis
Cells were stained with propidium iodide (40 mg/ml) containing RNase A (10 mg/ml) and analyzed using a fluorescence activated cell sorter (MACSQuant Analyzer) and MACSQuantify software.
Gene Expression Profiling and GSEA See Supplemental Experimental Procedures.
BiP ATPase Enzymatic Activity
Concentration-dependent spectrophotometric assays were carried out using recombinant human BiP protein (catalog no. ab78432; Abcam) at concentrations of 0.063, 0.125, 0.25, and 0.5 mM in 50 ml of assay buffer (20 mM Tris [pH 7.5], 50 mM KCl, 1.5 mM MgCl 2 ). The reaction was started by adding 100 mM ATP and incubating at 37 C for 30 min. Liberated free phosphate (Pi) was measured by a malachite green-phosphate assay (catalog no. 10009325; Cayman). The assay method is based on formation of a complex between malachite green molybdate and Pi (free orthophosphate) that absorbs at 620-640 nm. Assays to determine inhibition of ATPase activity were done with BiP (0.25 mM), with or without HA15 (0-100 mM).
Electron Microscopy
Electron microscopy experiments were performed as described .
Pull-Down Assay
Full-length recombinant BiP protein (20 mg) was incubated with HA15-biotin or biotin overnight at 4 C. Fifty microliters of streptavidin-agarose was added for 2 hr at 4 C. The HA15/BiP complex was analyzed by SDS-PAGE and immunoblotted using anti-BiP antibody.
In Vivo Murine Cancer Model
Animal experiments were carried out in accordance with French law and were approved by a local institutional ethical committee CIEPAL (Comité Institutionnel d'É thique Pour l'Animal de Laboratoire-Azur).
Circulating Levels of Transaminases
Determination of serum transaminases (aspartate aminotransferase/alanine aminotransferase) was performed using in vitro tests with pyridoxal phosphate activation on Roche/Hitachi cobas c systems (ASTPM, ALTPM, cobas).
Statistical Analysis
Results are presented as means ± SD with the number of experiments indicated in the figure legends. p % 0.05 was accepted as statistically significant.
ACCESSION NUMBERS
The experimental data are deposited in the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under the series record number GEO: GSE79071. independent experiments performed in triplicate. *, p < 0.05; **, p < 0.01; ***, p < 0.001. In parallel, cells were lysed and analyzed by western blotting using the indicated antibodies. HSP90 was used as a loading control.
SUPPLEMENTAL INFORMATION
Supplemental Experimental Procedures
BiP immunohistochemistry
Tissue specimens were fixed for 6 to 24 hr in 10 % formaldehyde and then paraffin embedded. IHC was performed on 3 µm tissue sections. All slides were freshly cut less than two weeks before IHC technique and stored at 4°C. Immunostaining were performed on Ventana® Benchmark immunostainer (Roche Diagnostics, Meylan, France) using the Ventana Ultraview detection kit©. Anti-BiP immunostaining (monoclonal rabbit antibody (cl:C50B12) provided by Cell Signaling) following the procedure: CC2© pretreatment for 60 min, antibody dilution at 1:200, incubation at 37 °C for 32 min. Melanoma was used as a positive control and secondary mouse or rabbit monoclonal antibodies alone as negative controls. The intensity and cellular (cytoplasm for BiP protein) localisation of the staining were analysed by 2 pathologists.
Gene expression profiling and GSEA
Total RNA of melanoma cells treated with or not with 10 µM HA15 was extracted using the RNeasy kit (Qiagen, Hilden, Germany). Integrity of RNA was assessed by using an Agilent BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input QuickAmp kit (Agilent) as recommended by the supplier. 825 ng of labeled cRNA probe were hybridized on 8×60 K high density SurePrint G3 gene expression mouse Agilent microarrays. Normalization of microarray data was performed using the Limma package available from Bioconductor (http://www.bioconductor.org). Inter slide normalization was performed using the quantile methods. Means of ratios from all comparisons were calculated and B test analysis was performed. Differentially expressed genes were selected based on a B-value above 0. GSEA was performed using gene sets from the Molecular Signatures Database. In brief, the method consists of the following steps: genes are first ranked in a list, L, by the correlation between their expression and the class distinction (for example, HA15 treated cells versus DMSO), using a suitable correlation metric. Given a defined set of genes S (for example, genes members of a signaling pathway), the goal of GSEA is to determine whether the members of S are found at the top or bottom of the list, indicating that they associate with the phenotypic distinction, rather than being distributed uniformly or randomly across the list. Next, to evaluate this degree of 'enrichment', an enrichment score is calculated to quantify the degree to which a set S is overrepresented at the top or bottom of the entire ranked list L. After calculation of the scores for a collection of gene sets, an empirical phenotype-based permutation test procedure is used to estimate P values. The permutation of class labels preserves gene-gene correlations and provides an assessment of significance that is more reflective of the underlying biology. Finally, an adjustment is made to the estimated significance level to account for multiple hypotheses testing. GSEA normalizes the enrichment score for each gene set to account for the variation in set sizes, yielding a NES and a FDR. The FDR gives an estimate of the probability that a set with a given NES represents a false-positive finding; it is computed by comparing the tails of the observed and permutationcomputed null distributions for the NES.
Proteomics analysis
Sample preparation: Protein from A375 melanoma cells were extracted in buffer containing TRIS-HCl pH 7.5 50 mM, NaCl 15 mM, Triton X-100 1 % and protease and phosphatase inhibitor 1X. Cell lysates (5 mg) were pre-cleared 1 hour at 4 °C with 40 µl of streptavidin-agarose breads (Sigma). Then lysates were incubated with 10 µM of HA15-Biotin and mixed at 4 °C overnight. After addition of 40 µl of streptavidin-agarose beads, the proteins linked by HA15 were precipitated 2 hr at 4 °C and separated by SDS-PAGE. Gel was colored in accordance with the manufacturer's instructions using Imperial Protein Stain (Thermo Scientific). Gel pieces containing proteins were excised and distained by adding 100 µL of H 2 O/ACN (1/1). After 10 min incubation with vortexing the liquid was discarded. This procedure was repeated 2 times. Gel piece were then rinced (15 min) with acetonitrile and dried under vaccum and were reswelled in 60 µL of 100mM DTT in NH 4 HCO 3 100 mM. There were incubated for 30 min at 56 °C next cooled down to RT. The DTT solution was replaced with 60 µL of 55 mM of iodoacetamide in 100 mM of NH 4 HCO 3 . After 15 min incubation at RT the solution was discarded and gel pieces were washed by adding successively i) 100 µL of H 2 O/ACN (1/1), repeated 2 times and ii) 100 µL of acetonitrile. Next gel pieces were reswelled in 60 µL of 50 mM NH 4 HCO 3 buffer containing 10 ng/µL of trypsin (modified porcine trypsin sequence grade, Promega) incubated for one hour at 4 °C. Then the solution was removed and replaced by 60 µL of 50 mM NH 4 HCO 3 buffer (without trypsin) and incubated 18 hr at 37 °C. After trypsin digestion the solution was transferred into an eppendorf tube and tryptic peptides were isolated by extraction with i) 50 µL of 1 % AF (acid formic) in water (10 min at RT) and ii) 50 µL acetonitrile
